Clinical trials: Squamous Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer, Non Small Cell Lung Cancer
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
The purpose of this study is to evaluate the safety and clinical activity of Apatinib in combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line chemotherapy in subjects with advanced EGFR wild…
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Combination Chemotherapy, Apatinib
- Trial name
- NCT03201146
- Testing
- Apatinib, AP or AC, Apatinib 250mg
- Where
- China
- Volunteers
- 48 people
- Sponsor
- West China Hospital
Lung Cancer Metastatic
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy" and not "chemotherapy". Laboratory tests show that it works by allowing the immune system to detect cancer and reactivate the immune…
- Trial name
- NCT03057106
- Testing
- Durvalumab, Tremelimumab, Platinum-Based Drug
- Where
- 49 sites in Australia, Canada
- Volunteers
- 301 people
- Sponsor
- Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT07662811
- Testing
- SYHX2011, Carboplatin, Enlonstobart
- Volunteers
- 396 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
Primary Objective The primary objective of this phase I-II study is to evaluate: Phase I: Assess the maximum tolerated dose (MTD) of bortezomib in a weekly schedule with bevacizumab given every 3 weeks.
- Trial name
- NCT00411593
- Testing
- Bevacizumab, Bortezomib
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).
- Trial name
- NCT06311721
- Testing
- ABP 234, Pembrolizumab (US), Pembrolizumab (EU)
- Where
- 218 sites in United States, Argentina and 21 more
- Volunteers
- 315 people
- Sponsor
- Amgen
NSCLC Stage IIIB, NSCLC Stage IV
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive
- Trial name
- GFPC 06-2018 (NCT04042558)
- Testing
- Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab
- Where
- 31 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Francois Baclesse
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is a randomized,Phase III, multicenter ,open-label study designed to evaluate the safety and efficacy of SHR-1210 with carboplatin and pemetrexed versus…
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
- Trial name
- NCT03134872
- Testing
- SHR-1210, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 419 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared…
- Trial name
- IMpower150 (NCT02366143)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin
- Where
- 240 sites in United States, Argentina and 24 more
- Volunteers
- 1,202 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00986297
- Testing
- hypofractionated radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Urothelial Carcinoma, Triple Negative Breast Cancer
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4…
- Conditions
- Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05234606
- Testing
- SBT6290, pembrolizumab
- Sponsor
- Silverback Therapeutics
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Gastric Cancer, Bladder Cancer
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.
- Conditions
- Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer, Cholangiocarcinoma
- Trial name
- NCT04149691
- Testing
- CPL304110
- Where
- 7 sites in Poland
- Volunteers
- 37 people
- Sponsor
- Celon Pharma SA
Lung Cancer
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of karenitecin in treating patients who have relapsed or…
- Trial name
- NCT00010218
- Testing
- karenitecin
- Where
- 44 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer
Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- ACDFNSNSCLC (NCT03750916)
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Volunteers
- 46 people
- Sponsor
- Qilu Hospital of Shandong University
Carcinoma, Non-Small -Cell Lung
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®).
- Trial name
- NCT06908304
- Testing
- 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel
- Where
- 15 sites in Poland, Romania and 2 more
- Volunteers
- 300 people
- Sponsor
- Maia Biotechnology
Lung Cancer
Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function
RATIONALE: Video-assisted surgery followed by radiation therapy may be an effective treatment in patients whose poor heart and lung function make them high risk for standard surgery.
- Trial name
- NCT00002624
- Testing
- adjuvant therapy, diagnostic thoracoscopy, therapeutic thoracoscopy
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 66 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small-Cell Lung
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
- Trial name
- NCT07489066
- Testing
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.